Collaborations
The path from scientific breakthrough to successful pharmaceutical brand depends on mobilizing the best global resources, expertise and experience.
At Novartis, we often achieve success through close collaboration with partners who share a common vision and complementary strengths. A key Novartis priority is to build winning collaborations in the research of new medicines and vaccines.
Read more about our alliances
(60 KB)
We are actively seeking partnerships in several therapeutic areas. Please explore your area of interest.
-
Oncology and Hematology
We are committed to building winning collaborations to provide healthcare solutions that address unmet needs for patients. In the area of Oncology and Hematology, we are interested in innovative and novel targets in all indications.
-
Cardiovascular and Metabolism
We are working to develop our business in the following indications:
- Diabetes
- Obesity
- Metabolic syndrome
- Atherosclerosis
- Novel treatments to improve lipid profile
- Innovative treatments for halting progression of congestive heart failure
- Antihypertensives with additional end organ benefits
-
Immunology and Infectious Diseases
We are working to develop our business in the following indications:
- Hepatitis C and B and other viral diseases
- Hospital specialty antibiotics
- Rheumatoid arthritis
- Osteoarthritis (including pain)
- Osteoporosis
- Muscle diseases, such as sarcopenia
- Immunomodulators for transplantation
- Treatment of end-stage and chronic renal disease
- Vascular access disease
-
Respiratory
We are working to develop our business in the following indications:
- Asthma
- Chronic obstructive pulmonary disease (COPD)
- Cystic fibrosis
- Idiopathic pulmonary fibrosis (IPF)
- Primary pulmonary hypertension (PPH)
-
Neuroscience and Ophthalmics
We are working to develop our business in the following indications:
- Neurodegeneration
- Multiple sclerosis
- Mood and anxiety disorders
- Psychotic disorders
- "Wet" age-related macular degeneration
- "Dry" age-related macular degeneration
- Glaucoma
-
Molecular Diagnostics
We are working to develop molecular diagnostics across our therapeutic areas.
For more information on Molecular Diagnostics partnership opportunities, please visit Novartis Molecular Diagnostics
For other inquiries, please contact:
Novartis Pharmaceuticals Business Development & LicensingCH-4002 Basel
Switzerland
Information you supply to us
Except for information covered by our Privacy Policy, any communication or material you transmit to the Site by electronic mail or otherwise, including any data, questions comments,suggestions or the like is, and will be treated as non-confidential and nonproprietary. Novartis will not accept information identified as confidential until a confidentiality agreement is executed between Novartis and your organization. Any information identified as confidential sent to Novartis will be deleted without being read.
